/
PBM
$3.56+$0.21 (+6.27%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$12.8M
4M shares
52-week range
$1.92 – $34.63
5% from low
Exchange
NASDAQ
CS
Change$-8775.90
Psyence Biomedical Ltd. Common Shares
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.
www.psyence.com- Employees
- 12
- IPO / List date
- Jan 26, 2024
Held by traders on TradeandTell
No one on the platform currently holds PBM.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in PBM as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2026-02-02 | 1-for-6.25reverse |
| 2025-05-05 | 1-for-7.97reverse |
| 2024-11-26 | 1-for-75reverse |
Recent trades on TradeandTell
No one on the platform has traded PBM yet.
